trending Market Intelligence /marketintelligence/en/news-insights/trending/3UB2v6s7NyEFAB8QVXcE5Q2 content esgSubNav
In This List

Amgen negotiates extension in $2.5B credit agreement

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Amgen negotiates extension in $2.5B credit agreement

Amgen Inc. amended a 2014 credit agreement with certain financial institutions, negotiating an extension to the agreement's maturity.

The Thousand Oaks, Calif.-based biotech company's credit limit is set at $2.5 billion, and the agreement now matures in December 2024, extendable by up to two years at Amgen's request.

Amgen may also request an increase of up to $750 million in its credit limit.

Amgen plans to use the borrowings for general corporate purposes.